Compare GSK plc (GSK) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Williams-Sonoma, Inc. — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: GSK plc is far larger — about 3.3× Williams-Sonoma, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Williams-Sonoma, Inc. for 59 Days on average.
| GSK | WSM | |
|---|---|---|
Market Cap | $91.88B | $28.15B |
Volume | 7,730,529 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $251.81 |
52-Week Low | $43.24 | $168.64 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $111.88B | $28.65B |
Dividend Yield | 3.9% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Williams-Sonoma (WSM) trades at $241.78, up 0.55% on the day, reflecting strong momentum near its consensus price target of $246.31. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 14.73% net income margin and consistent earnings beats in recent quarters. Recent news highlights market share gains and profitability improvements, with the company raising full-year guidance after strong Q2 2026 results.
The outlook remains positive given WSM's operational efficiency and dividend growth, though risks include housing market sensitivity and competitive pressures. Analyst consensus leans bullish with 32% buy ratings, but high valuation multiples like a P/E of 24.51 warrant caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
